Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2173-2177

  Collins, Vicki L ^a   Marchaim, Dror ^a   Pogue, Jason M ^b   Moshos, Judy ^a   Bheemreddy, Suchitha ^a   Sunkara, Bharath ^a   Shallal, Alex ^a   Chugh, Neelu ^a   Eiseler, Sara ^a   Bhargava, Pragati ^a   Blunden, Christopher ^a   Lephart, Paul R ^b   Memon, Babar Irfan ^a   Hayakawa, Kayoko ^a   Abreu Lanfranco, Odaliz ^a   Chopra, Teena ^a   Munoz Price, L Silvia ^c   Carmeli, Yehuda ^d   Kaye, Keith S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; IMIPENEM; MEROPENEM;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MCCABE SCORE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPSIS; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; COHORT STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84858627256     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05913-11     Document Type: Article

References (31)

1. Andremont A, et al. 2011. Fighting bacterial resistance at the root: need for adapted EMEA guidelines. Lancet Infect. Dis. 11:6-8.
2. Bazaz R, Chapman AL, Winstanley TG. 2010. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J. Antimicrob. Chemother. 65:1510-1513.
3. Berg ML, Crank CW, Philbrick AH, Hayden MK. 2008. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing Gram-negative infections: a case series report. Ann. Pharmacother. 42:207-212. (Pubitemid 351238568)
4. Bin C, et al. 2006. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn. Microbiol. Infect. Dis. 56:351-357. (Pubitemid 44854354)
5. Bion JF, Edlin SA, Ramsay G, McCabe S, Ledingham IM. 1985. Validation of a prognostic score in critically ill patients undergoing transport. Br. Med. J. (Clin. Res. Ed.) 291:432-434. (Pubitemid 15012888)
6. Bonfiglio G, Russo G, Nicoletti G. 2002. Recent developments in carbapenems. Expert Opin. Investig. Drugs 11:529-544. (Pubitemid 34450123)
7. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
8. Burgess DS, Hall RG, II, Lewis JS, II, Jorgensen JH, Patterson JE. 2003. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 23:1232-1237. (Pubitemid 37221917)
9. CLSI. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Approved standard M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Curran M, Simpson D, Perry C. 2003. Ertapenem: a review of its use in the management of bacterial infections. Drugs 63:1855-1878. (Pubitemid 37083031)
11. Dellinger RP, et al. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36:296-327.
12. Endimiani A, et al. 2004. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis. 38:243-251. (Pubitemid 38113033)
13. Gesser RM, McCarroll K, Teppler H, Woods GL. 2003. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J. Antimicrob. Chemother. 51:1253-1260. (Pubitemid 36622082)
14. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. 2002. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand. J. Infect. Dis. 34:567-573. (Pubitemid 35012337)
15. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332. (Pubitemid 351763841)
16. Hyle EP, Ferraro MJ, Silver M, Lee H, Hooper DC. 2010. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes. Infect. Control Hosp. Epidemiol. 31:1242-1249.
17. Kang CI, et al. 2004. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 25:860-867.
18. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. 1963. Studies of illness in the aged. The Index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914-919.
19. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. 2002. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J. Hosp. Infect. 52:99-106. (Pubitemid 38001939)
20. Leavitt A, et al. 2009. Ertapenem resistance among extended-spectrum- beta-lactamase-producing Klebsiella pneumoniae isolates. J. Clin. Microbiol. 47:969-974.
21. Lee CH, Su LH, Tang YF, Liu JW. 2006. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J. Antimicrob. Chemother. 58:1074-1077.
22. Navarro NS, Jr, et al. 2005. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int. J. Surg. 3:25-34.
23. Ortiz-Ruiz G, et al. 2004. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J. Antimicrob. Chemother. 53(Suppl 2):ii59-ii66.
24. Paterson DL, et al. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect. Dis. 39:31-37. (Pubitemid 38879546)
25. Peleg AY, Hooper DC. 2010. Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med. 362:1804-1813.
26. Pitout JD, Laupland KB. 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. (Pubitemid 351249250)
27. Solomkin J, et al. 2004. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J. Antimicrob. Chemother. 53(Suppl 2):ii51-ii57.
28. Tice AD. 2004. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J. Antimicrob. Chemother. 53(Suppl 2):ii83-ii86.
29. Vetter N, et al. 2002. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. 24:1770-1785. (Pubitemid 35440949)
30. Wells WG, Woods GL, Jiang Q, Gesser RM. 2004. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J. Antimicrob. Chemother. 53(Suppl 2):ii67-ii74.
31. Zanetti G, et al. 2003. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob. Agents Chemother. 47:3442-3447. (Pubitemid 37345702)